Geopolitical pressures and greater buyer selectivity hamper M&A deal closure rates
While M&A appetite has been strong in 2026, deals are increasingly thwarted by valuation gaps, geopolitical uncertainty and greater selectivity…
While M&A appetite has been strong in 2026, deals are increasingly thwarted by valuation gaps, geopolitical uncertainty and greater selectivity…
The longevity market is gaining significant traction, with capital investment and deal count at a record high for 2025 and…
While Europe is often lauded for its robust science, late-stage investment has historically been challenging to secure. Yet speakers at…
In the age of AI, pharma and tech companies are increasingly joining forces. Inevitably, such collaboration demands a strong digital…
Despite fostering cutting-edge science, gene therapy biotechs have sometimes failed to reach commercial heights due to inherent scalability hurdles. Consequently,…
Note: A few hours after this article was published, oveporexton was approved as a treatment for narcolepsy type 1. More…
Following an influx of capital in the early COVID-19 pandemic, the biotech sector entered a sustained investment slump. Now the…
Following decades of stagnant research, psychedelic-assisted therapy has been heralded as a potentially transformative approach amid a global mental health…
In April, Ipsen’s Ojemda (tovorafenib) secured European Commission (EC) approval for the treatment of relapsed or refractory paediatric low-grade glioma.…
Endometriosis affects an estimated 10% of reproductive-age women worldwide. Early diagnosis is crucial for preventing disease progression, improving pain management,…